Aktie A2QLP9 VICS VANT
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen VICS VANT

Aktien

A2QLP9

KYG9440B1077

VCKA

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics Inc. Debuts on Nasdaq Under Ticker 'SCLX'
Vickers Vantage Corp. I(NasdaqCM:VCKA) dropped from NASDAQ Composite Index
Scilex Holding Company completed the acquisition of Vickers Vantage Corp. I from Vickers Venture Fund VI L.P. and Vickers Venture Fund VI Pte Ltd, managed by Vickers Venture Partners, Shaolin Capital Management LLC, Hudson Bay Capital Management LP and others in a reverse merger transaction.
VICKERS VANTAGE CORP. I : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
VICKERS VANTAGE CORP. I Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Vickers Vantage Corp. I Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Scilex Holding Company a Sorrento Company and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
Vickers Vantage I : Merger Agreement - Form 8-K
VICKERS VANTAGE CORP. I : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
VICKERS VANTAGE CORP. I : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 5.4%, Next Generation Triple Strength Formulation of ZTlido, For the Treatment of Acute Low Back Pain
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido
Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers
VICKERS VANTAGE CORP. I Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Vickers Vantage Corp. I Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Sorrento Therapeutics Unit Scilex Plans to Acquire Ancora Medical
Vickers Vantage I : Announces Shareholder Approval of Extension of Deadline to Complete Business Combination – Form 8-K
Vickers Vantage I : Announces Shareholder Approval of Extension of Deadline to Complete Business Combination - Form 8-K
VICKERS VANTAGE CORP. I : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QLP9 Aktie
  4. Nachrichten VICS VANT
  5. Andere Sprachen